Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) hit a new 52-week high on Friday . The stock traded as high as $50.40 and last traded at $50.21, with a volume of 40703 shares. The stock had previously closed at $48.65.
Analyst Upgrades and Downgrades
Several research analysts have commented on BLTE shares. Benchmark restated a “buy” rating and set a $57.00 price objective on shares of Belite Bio in a report on Thursday, May 16th. HC Wainwright reaffirmed a “buy” rating and set a $59.00 price objective on shares of Belite Bio in a research report on Thursday, June 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Belite Bio in a research report on Thursday, June 20th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $44.83.
Check Out Our Latest Research Report on BLTE
Belite Bio Trading Up 4.0 %
Belite Bio (NASDAQ:BLTE – Get Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.07. On average, research analysts anticipate that Belite Bio, Inc will post -1.08 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Belite Bio stock. Jump Financial LLC purchased a new stake in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 5,200 shares of the company’s stock, valued at approximately $238,000. 0.53% of the stock is currently owned by institutional investors and hedge funds.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
Featured Articles
- Five stocks we like better than Belite Bio
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Is This Telehealth Stock a Buy After the Recent Pullback?
- 3 Warren Buffett Stocks to Buy Now
- Safeguard Against Credit Card Risks with This Top Financial Stock
- 3 Best Fintech Stocks for a Portfolio Boost
- Streaming Titan’s Stock Ready to Hit All-Time Highs This Year
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.